Merck Ebola Vaccine, Gilead Antiviral Drug Set for Wider Use in Congo Outbreak

Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences Inc. are slated for expanded deployment in eastern Democratic Republic of Congo to combat the rapidly growing Ebola outbreak.

7 Aug, 03:07 — 7 Aug, 03:07

Post Share

Sources

Showing 1 of 1 sources

bloombergHigh1h ago

Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Merck & Co.’s Ebola vaccine and an antiviral drug from Gilead Sciences Inc. are set for wider use in eastern Democratic Republic of Congo to blunt the fastest-growing Ebola outbreak on record.

By Janice Kew and Jason Gale

Read full article →

PERSPECTA

PERSPECTA

Merck Ebola Vaccine, Gilead Antiviral Drug Set for Wider Use in Congo Outbreak

Sources

Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Related Stories

Prof. Tsvetalina Tankova: Obesity is a chronic disease and should be treated

Assoc. Prof. Rosen Kalpachki: Neglect of health, lack of elder care, and poverty are main causes of shorter life expectancy

Record-dry July in Western Cape raises water concerns amid strengthening El Niño

Heavy Rain Batters Kerala, Red Alert Issued for Seven Districts

PERSPECTA